Assenagon Asset Management
ADMS

Assenagon Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Assenagon Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-123,479
Closed -$593K – 1480
2021
Q1 		$593K Sell
123,479
-2,221
-2% -$11.6K ﹤0.01% 1010
2020
Q4 		$544K Sell
125,700
-530,557
-81% -$2.27M ﹤0.01% 838
2020
Q3 		$2.7M Sell
656,257
-94,691
-13% -$366K 0.02% 509
2020
Q2 		$1.92M Buy
+750,948
New +$2.21M 0.01% 615
2019
Q1 		– Sell
-18,822
Closed -$161K – 1174
2018
Q4 		$161K Buy
+18,822
New +$245K ﹤0.01% 970

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Assenagon Asset Management's ADMS Position: Q2 2021 in Review

Assenagon Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q2 2021, closing a stake of 123,479 shares — an estimated $593K sold.

Assenagon Asset Management first reported a position in ADMS in Q4 2018 and held it in 5 quarters. The position peaked at $2.7M in Q3 2020. 67 funds tracked by Wall St. Rank hold ADMS as of Q2 2021.

  • Assenagon Asset Management reported no remaining Adamas Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Assenagon Asset Management sold 123,479 Adamas Pharmaceuticals shares in Q2 2021, an estimated $593K.
  • Assenagon Asset Management first reported a position in Adamas Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • Assenagon Asset Management's Adamas Pharmaceuticals position peaked at $2.7M in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2021.

Based on Assenagon Asset Management's 13F filing for Q2 2021, filed 15 Jul 2021.